Literature DB >> 32090197

Prognostic value of Sjögren's syndrome autoantibodies.

R Hal Scofield1,2,3, Anum Fayyaz1,2,3, Biji T Kurien1,2,3, Kristi A Koelsch1,2,3.   

Abstract

Sjögren's syndrome is in part considered an autoimmune disease because patient sera contain antibodies binding self-structures. In fact, in addition to anti-Ro (or SSA) and anti-La (or SSB), which are included in the classification criteria, there are a wide variety of autoantibodies found among these patients. We reviewed English-language MEDLINE sources. Anti-Ro and anti-La found among healthy individuals, including mothers giving birth to infants with neonatal lupus, predicts future connective tissue disease. Those with Sjögren's syndrome can be divided into two groups; patients with only exocrine gland involvement and those with systemic disease. The presence of anti-Ro/La is associated with systemic, extraglandular disease. Rheumatoid factor is also associated with extraglandular disease while anti-cyclic citrullinated peptide (CCP) is likely associated with inflammatory arthritis and progression to rheumatoid arthritis. Anti-mitochondrial antibodies are uncommon but predict progression to primary biliary cirrhosis. Cryoglobulinemia is found in excess among those with non-Hodgkin's lymphoma. Determination of autoantibodies on the sera of Sjögren's syndrome patients has prognostic implications for Sjögren's syndrome itself as well as associated diseases.

Entities:  

Keywords:  Sjögren’s syndrome; autoantibodies; congenital heart block; prognosis

Year:  2018        PMID: 32090197      PMCID: PMC7034933          DOI: 10.21037/jlpm.2018.08.05

Source DB:  PubMed          Journal:  J Lab Precis Med        ISSN: 2519-9005


  113 in total

1.  Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a 5 year follow-up.

Authors:  A Csepregi; P Szodoray; M Zeher
Journal:  Scand J Immunol       Date:  2002-12       Impact factor: 3.487

2.  IgA rheumatoid factor in primary Sjogren's syndrome.

Authors:  E Peen; O J Mellbye; H-J Haga
Journal:  Scand J Rheumatol       Date:  2009 Jan-Feb       Impact factor: 3.641

3.  Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma.

Authors:  A C Gelber; S R Pillemer; B J Baum; F M Wigley; L K Hummers; S Morris; A Rosen; L Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

4.  Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.

Authors:  F N Skopouli; U Dafni; J P Ioannidis; H M Moutsopoulos
Journal:  Semin Arthritis Rheum       Date:  2000-04       Impact factor: 5.532

5.  [The autoantibody profile in Sjögren's syndrome].

Authors:  M N Manoussakis; P J Pange; H M Moutsopulos
Journal:  Ter Arkh       Date:  1988       Impact factor: 0.467

Review 6.  Passively acquired autoimmunity and the maternal fetal dyad in systemic lupus erythematosus.

Authors:  J Buyon; I Szer
Journal:  Springer Semin Immunopathol       Date:  1986

7.  The Ro autoantigen binds misfolded U2 small nuclear RNAs and assists mammalian cell survival after UV irradiation.

Authors:  Xinguo Chen; James D Smith; Hong Shi; Derek D Yang; Richard A Flavell; Sandra L Wolin
Journal:  Curr Biol       Date:  2003-12-16       Impact factor: 10.834

Review 8.  Autoantibodies as predictors of disease.

Authors:  R Hal Scofield
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

9.  Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue.

Authors:  Claudio Vitali; Hendrika Bootsma; Simon J Bowman; Thomas Dorner; Jacques-Eric Gottenberg; Xavier Mariette; Manuel Ramos-Casals; Philippe Ravaud; Raphaele Seror; Elke Theander; Athanasios G Tzioufas
Journal:  Ann Rheum Dis       Date:  2012-12-22       Impact factor: 19.103

10.  Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use.

Authors:  Sofia Fragkioudaki; Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more
  3 in total

Review 1.  The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned.

Authors:  Harini Bagavant; Aleksandra Michrowska; Umesh S Deshmukh
Journal:  Autoimmun Rev       Date:  2020-10-22       Impact factor: 9.754

2.  NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.

Authors:  Elena Pontarini; Elisabetta Sciacca; Sofia Grigoriadou; Felice Rivellese; Davide Lucchesi; Liliane Fossati-Jimack; Rachel Coleby; Farzana Chowdhury; Francesca Calcaterra; Anwar Tappuni; Myles J Lewis; Martina Fabris; Luca Quartuccio; Silvia Della Bella; Simon Bowman; Costantino Pitzalis; Domenico Mavilio; Salvatore De Vita; Michele Bombardieri
Journal:  Front Immunol       Date:  2021-09-14       Impact factor: 7.561

3.  Mapping Salivary Proteases in Sjögren's Syndrome Patients Reveals Overexpression of Dipeptidyl Peptidase-4/CD26.

Authors:  Laís Garreto; Sébastien Charneau; Samuel Coelho Mandacaru; Otávio T Nóbrega; Flávia N Motta; Carla N de Araújo; Audrey C Tonet; Flávia M B Modesto; Lilian M Paula; Marcelo Valle de Sousa; Jaime M Santana; Ana Carolina Acevedo; Izabela M D Bastos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.